---
title: 'Magrolimab Plus Rituximab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma:
  Phase 1/2 Trial 3-Year Follow-up'
date: '2024-08-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39213421/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240831181334&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) is generally
  considered incurable with current treatment options. Previous phase 1b/2 results
  showed combining the anti-cluster-of-differentiation (CD) 47 activity of magrolimab
  with the anti-CD20 activity of rituximab (M+R) has antitumor activity against R/R
  iNHL. Here, we report 3-year follow-up data from this phase 1b/2 study (NCT02953509)
  assessing long-term safety and efficacy of M+R in R/R iNHL. After magrolimab priming,
  ...
disable_comments: true
---
Relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) is generally considered incurable with current treatment options. Previous phase 1b/2 results showed combining the anti-cluster-of-differentiation (CD) 47 activity of magrolimab with the anti-CD20 activity of rituximab (M+R) has antitumor activity against R/R iNHL. Here, we report 3-year follow-up data from this phase 1b/2 study (NCT02953509) assessing long-term safety and efficacy of M+R in R/R iNHL. After magrolimab priming, ...